| Předmět: |
|
| Zdroj: |
AIDS Weekly; 3/20/2023, p57-57, 1p |
| Abstrakt: |
Keywords: Collegeville; State:Pennsylvania; United States; North and Central America; Acquired Immunodeficiency Syndrome; Biological Products; Business; Clinical Research; Clinical Trials and Studies; Epidemiology; GlaxoSmithKline plc; HIV/AIDS; Health and Medicine; Immune System Diseases and Conditions; Immunization; Immunization and Public Health; Pharmaceutical Companies; Primate Lentiviruses; RNA Viruses; Retroviridae; Vaccination; Vaccines; Vertebrate Viruses; Viral Sexually Transmitted Diseases and Conditions; Virology EN Collegeville State:Pennsylvania United States North and Central America Acquired Immunodeficiency Syndrome Biological Products Business Clinical Research Clinical Trials and Studies Epidemiology GlaxoSmithKline plc HIV/AIDS Health and Medicine Immune System Diseases and Conditions Immunization Immunization and Public Health Pharmaceutical Companies Primate Lentiviruses RNA Viruses Retroviridae Vaccination Vaccines Vertebrate Viruses Viral Sexually Transmitted Diseases and Conditions Virology 57 57 1 03/23/23 20230320 NES 230320 2023 MAR 20 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Research findings on Immune System Diseases and Conditions - HIV/AIDS are discussed in a new report. GSK-sponsored interventional phase I-IV clinical trials conducted from 2002 to 2019 across three areas were analyzed: pharmaceutical (includes therapeutic medicines except for vaccines and human immunodeficiency virus (HIV)), vaccine (includes prophylactic and therapeutic vaccines), and ViiV (includes HIV therapies). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
